Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS.

Valoti E, Alberti M, Iatropoulos P, Piras R, Mele C, Breno M, Cremaschi A, Bresin E, Donadelli R, Alizzi S, Amoroso A, Benigni A, Remuzzi G, Noris M.

Front Immunol. 2019 May 1;10:853. doi: 10.3389/fimmu.2019.00853. eCollection 2019.

2.

Hemolytic Uremic Syndrome in an Infant with Primary Hyperoxaluria Type II: An Unreported Clinical Association.

Valoti E, Alberti M, Carrara C, Breno M, Yilmaz Keskin E, Bresin E, Cuccarolo P, Açikgöz Y, Benigni A, Noris M, Remuzzi G, Mele C.

Nephron. 2019;142(3):264-270. doi: 10.1159/000497823. Epub 2019 Mar 19.

PMID:
30889567
3.

An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome.

Galbusera M, Noris M, Gastoldi S, Bresin E, Mele C, Breno M, Cuccarolo P, Alberti M, Valoti E, Piras R, Donadelli R, Vivarelli M, Murer L, Pecoraro C, Ferrari E, Perna A, Benigni A, Portalupi V, Remuzzi G.

Am J Kidney Dis. 2019 Jul;74(1):56-72. doi: 10.1053/j.ajkd.2018.11.012. Epub 2019 Mar 7.

PMID:
30851964
4.

Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.

Donadelli R, Pulieri P, Piras R, Iatropoulos P, Valoti E, Benigni A, Remuzzi G, Noris M.

Front Immunol. 2018 Oct 15;9:2329. doi: 10.3389/fimmu.2018.02329. eCollection 2018.

5.

How Reaction Conditions May Influence the Regioselectivity in the Synthesis of 2,3-Dihydro-1,4-benzoxathiine Derivatives.

Casiraghi A, Valoti E, Suigo L, Artasensi A, Sorvillo E, Straniero V.

J Org Chem. 2018 Nov 2;83(21):13217-13227. doi: 10.1021/acs.joc.8b02012. Epub 2018 Oct 11.

PMID:
30265535
6.

Oral Bioavailability and Pharmacokinetics of Nonanimal Chondroitin Sulfate and Its Constituents in Healthy Male Volunteers.

Volpi N, Mantovani V, Galeotti F, Bianchi D, Straniero V, Valoti E, Miraglia N.

Clin Pharmacol Drug Dev. 2019 Apr;8(3):336-345. doi: 10.1002/cpdd.587. Epub 2018 Jul 24.

PMID:
30040242
7.

Stressed degradation studies of domiphen bromide by LC-ESI-MS/MS identify a novel promising antimicrobial agent.

Fumagalli L, Regazzoni LG, Straniero V, Valoti E, Aldini G, Vistoli G, Carini M, Picozzi C.

J Pharm Biomed Anal. 2018 Sep 10;159:224-228. doi: 10.1016/j.jpba.2018.06.055. Epub 2018 Jun 30.

PMID:
29990889
8.

How do reaction conditions affect the enantiopure synthesis of 2-substituted-1,4-benzodioxane derivatives?

Straniero V, Casiraghi A, Fumagalli L, Valoti E.

Chirality. 2018 Jul;30(7):943-950. doi: 10.1002/chir.22968. Epub 2018 May 12.

PMID:
29752740
9.

Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.

Iatropoulos P, Daina E, Curreri M, Piras R, Valoti E, Mele C, Bresin E, Gamba S, Alberti M, Breno M, Perna A, Bettoni S, Sabadini E, Murer L, Vivarelli M, Noris M, Remuzzi G; Registry of Membranoproliferative Glomerulonephritis/C3 Glomerulopathy; Nastasi.

J Am Soc Nephrol. 2018 Jan;29(1):283-294. doi: 10.1681/ASN.2017030258. Epub 2017 Oct 13.

10.

2,6-Difluorobenzamide Inhibitors of Bacterial Cell Division Protein FtsZ: Design, Synthesis, and Structure-Activity Relationships.

Straniero V, Zanotto C, Straniero L, Casiraghi A, Duga S, Radaelli A, De Giuli Morghen C, Valoti E.

ChemMedChem. 2017 Aug 22;12(16):1303-1318. doi: 10.1002/cmdc.201700201. Epub 2017 Jul 11.

PMID:
28586174
11.

The Feasibility of a Completely Automated Total IV Anesthesia Drug Delivery System for Cardiac Surgery.

Zaouter C, Hemmerling TM, Lanchon R, Valoti E, Remy A, Leuillet S, Ouattara A.

Anesth Analg. 2016 Oct;123(4):885-93. doi: 10.1213/ANE.0000000000001152.

PMID:
27644009
12.

3-(Benzodioxan-2-ylmethoxy)-2,6-difluorobenzamides bearing hydrophobic substituents at the 7-position of the benzodioxane nucleus potently inhibit methicillin-resistant Sa and Mtb cell division.

Straniero V, Pallavicini M, Chiodini G, Zanotto C, Volontè L, Radaelli A, Bolchi C, Fumagalli L, Sanguinetti M, Menchinelli G, Delogu G, Battah B, De Giuli Morghen C, Valoti E.

Eur J Med Chem. 2016 Sep 14;120:227-43. doi: 10.1016/j.ejmech.2016.03.068. Epub 2016 Mar 28.

PMID:
27191617
13.
14.

Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.

Iatropoulos P, Noris M, Mele C, Piras R, Valoti E, Bresin E, Curreri M, Mondo E, Zito A, Gamba S, Bettoni S, Murer L, Fremeaux-Bacchi V, Vivarelli M, Emma F, Daina E, Remuzzi G.

Mol Immunol. 2016 Mar;71:131-142. doi: 10.1016/j.molimm.2016.01.010. Epub 2016 Feb 16.

PMID:
26895476
15.

Behavioural and pharmacological characterization of a novel cannabinomimetic adamantane-derived indole, APICA, and considerations on the possible misuse as a psychotropic spice abuse, in C57bl/6J mice.

Cannizzaro C, Malta G, Argo A, Brancato A, Roda G, Casagni E, Fumagalli L, Valoti E, Froldi R, Procaccianti P, Gambaro V.

Forensic Sci Int. 2016 Aug;265:6-12. doi: 10.1016/j.forsciint.2015.12.035. Epub 2016 Jan 6.

16.

A selective alpha1D-adrenoreceptor antagonist inhibits human prostate cancer cell proliferation and motility "in vitro".

Colciago A, Mornati O, Ferri N, Castelnovo LF, Fumagalli L, Bolchi C, Pallavicini M, Valoti E, Negri-Cesi P.

Pharmacol Res. 2016 Jan;103:215-26. doi: 10.1016/j.phrs.2015.11.017. Epub 2015 Nov 24.

17.

Association of CFHR1 homozygous deletion with acute myelogenous leukemia in the European population.

Fratelli M, Bolis M, Kurosaki M, Dori M, Guarnaccia V, Spinelli O, Alberti M, Valoti E, Pileggi S, Noris M, Remuzzi G, Rambaldi A, Terao M, Garattini E.

Leuk Lymphoma. 2016 May;57(5):1234-7. doi: 10.3109/10428194.2015.1082180. Epub 2016 Mar 2. No abstract available.

PMID:
26317246
18.

Chemistry and Pharmacology of a Series of Unichiral Analogues of 2-(2-Pyrrolidinyl)-1,4-benzodioxane, Prolinol Phenyl Ether, and Prolinol 3-Pyridyl Ether Designed as α4β2-Nicotinic Acetylcholine Receptor Agonists.

Bolchi C, Valoti E, Gotti C, Fasoli F, Ruggeri P, Fumagalli L, Binda M, Mucchietto V, Sciaccaluga M, Budriesi R, Fucile S, Pallavicini M.

J Med Chem. 2015 Aug 27;58(16):6665-77. doi: 10.1021/acs.jmedchem.5b00904. Epub 2015 Aug 18.

PMID:
26225816
19.

Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome.

Mele C, Lemaire M, Iatropoulos P, Piras R, Bresin E, Bettoni S, Bick D, Helbling D, Veith R, Valoti E, Donadelli R, Murer L, Neunhäuserer M, Breno M, Frémeaux-Bacchi V, Lifton R, Remuzzi G, Noris M.

Clin J Am Soc Nephrol. 2015 Jun 5;10(6):1011-9. doi: 10.2215/CJN.08520814. Epub 2015 Apr 8.

20.

Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome.

Schramm EC, Roumenina LT, Rybkine T, Chauvet S, Vieira-Martins P, Hue C, Maga T, Valoti E, Wilson V, Jokiranta S, Smith RJ, Noris M, Goodship T, Atkinson JP, Fremeaux-Bacchi V.

Blood. 2015 Apr 9;125(15):2359-69. doi: 10.1182/blood-2014-10-609073. Epub 2015 Jan 21.

21.

Benzodioxane-benzamides as new bacterial cell division inhibitors.

Chiodini G, Pallavicini M, Zanotto C, Bissa M, Radaelli A, Straniero V, Bolchi C, Fumagalli L, Ruggeri P, De Giuli Morghen C, Valoti E.

Eur J Med Chem. 2015 Jan 7;89:252-65. doi: 10.1016/j.ejmech.2014.09.100. Epub 2014 Oct 18.

PMID:
25462242
22.

Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.

Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, Tripodo C, Bettoni S, Donadelli R, Valoti E, Tedesco F, Amore A, Coppo R, Ruggenenti P, Gotti E, Remuzzi G.

Blood. 2014 Sep 11;124(11):1715-26. doi: 10.1182/blood-2014-02-558296. Epub 2014 Jul 18.

23.

From 2-aminomethyl-1,4-benzodioxane enantiomers to unichiral 2-cyano- and 2-carbonyl-substituted benzodioxanes via dichloroamine.

Bolchi C, Valoti E, Straniero V, Ruggeri P, Pallavicini M.

J Org Chem. 2014 Jul 18;79(14):6732-7. doi: 10.1021/jo500964y. Epub 2014 Jun 26.

PMID:
24945589
24.

A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation.

Valoti E, Alberti M, Tortajada A, Garcia-Fernandez J, Gastoldi S, Besso L, Bresin E, Remuzzi G, Rodriguez de Cordoba S, Noris M.

J Am Soc Nephrol. 2015 Jan;26(1):209-19. doi: 10.1681/ASN.2013121339. Epub 2014 Jun 5.

25.

Farnesyltransferase inhibitors: CAAX mimetics based on different biaryl scaffolds.

Straniero V, Pallavicini M, Chiodini G, Ruggeri P, Fumagalli L, Bolchi C, Corsini A, Ferri N, Ricci C, Valoti E.

Bioorg Med Chem Lett. 2014 Jul 1;24(13):2924-7. doi: 10.1016/j.bmcl.2014.04.078. Epub 2014 Apr 30.

PMID:
24821376
26.

Characterization of in vitro metabolites of JWH-018, JWH-073 and their 4-methyl derivatives, markers of the abuse of these synthetic cannabinoids.

Gambaro V, Arnoldi S, Bellucci S, Casagni E, Dell'Acqua L, Fumagalli L, Pallavicini M, Roda G, Rusconi C, Valoti E.

J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Apr 15;957:68-76. doi: 10.1016/j.jchromb.2014.03.001. Epub 2014 Mar 12.

PMID:
24657413
27.

Design, synthesis and binding affinity of acetylcholine carbamoyl analogues.

Bolchi C, Valoti E, Binda M, Fasoli F, Ferrara R, Fumagalli L, Gotti C, Matucci R, Vistoli G, Pallavicini M.

Bioorg Med Chem Lett. 2013 Dec 1;23(23):6481-5. doi: 10.1016/j.bmcl.2013.09.023. Epub 2013 Sep 18.

PMID:
24128660
28.

6-methoxy-7-benzofuranoxy and 6-methoxy-7-indolyloxy analogues of 2-[2-(2,6-Dimethoxyphenoxy)ethyl]aminomethyl-1,4-benzodioxane (WB4101):1 discovery of a potent and selective α1D-adrenoceptor antagonist.

Fumagalli L, Pallavicini M, Budriesi R, Bolchi C, Canovi M, Chiarini A, Chiodini G, Gobbi M, Laurino P, Micucci M, Straniero V, Valoti E.

J Med Chem. 2013 Aug 22;56(16):6402-12. doi: 10.1021/jm400867d. Epub 2013 Jul 31.

PMID:
23902232
29.

Exploring the space of histidine containing dipeptides in search of novel efficient RCS sequestering agents.

Vistoli G, De Maddis D, Straniero V, Pedretti A, Pallavicini M, Valoti E, Carini M, Testa B, Aldini G.

Eur J Med Chem. 2013 Aug;66:153-60. doi: 10.1016/j.ejmech.2013.05.009. Epub 2013 May 30.

PMID:
23792353
30.

Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature.

Manenti L, Gnappi E, Vaglio A, Allegri L, Noris M, Bresin E, Pilato FP, Valoti E, Pasquali S, Buzio C.

Nephrol Dial Transplant. 2013 Sep;28(9):2246-59. doi: 10.1093/ndt/gft220. Epub 2013 Jun 19. Review.

PMID:
23787552
31.

Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations.

Alberti M, Valoti E, Piras R, Bresin E, Galbusera M, Tripodo C, Thaiss F, Remuzzi G, Noris M.

Am J Transplant. 2013 Aug;13(8):2201-6. doi: 10.1111/ajt.12297. Epub 2013 Jun 3.

32.

Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype.

Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, Pinto S, Goodship TH, Alberti M, Ribes D, Valoti E, Remuzzi G, Noris M; European Working Party on Complement Genetics in Renal Diseases.

J Am Soc Nephrol. 2013 Feb;24(3):475-86. doi: 10.1681/ASN.2012090884. Epub 2013 Feb 21.

33.

Affinity and activity profiling of unichiral 8-substituted 1,4-benzodioxane analogues of WB4101 reveals a potent and selective α1B-adrenoceptor antagonist.

Fumagalli L, Pallavicini M, Budriesi R, Gobbi M, Straniero V, Zagami M, Chiodini G, Bolchi C, Chiarini A, Micucci M, Valoti E.

Eur J Med Chem. 2012 Dec;58:184-91. doi: 10.1016/j.ejmech.2012.09.049. Epub 2012 Oct 16.

PMID:
23124215
34.

Identification of 1-butyl-3-(1-(4-methyl)naphtoyl)indole detected for the first time in "herbal high" products on the Italian market.

Valoti E, Casagni E, Dell'Acqua L, Pallavicini M, Roda G, Rusconi C, Straniero V, Gambaro V.

Forensic Sci Int. 2012 Nov 30;223(1-3):e42-6. doi: 10.1016/j.forsciint.2012.08.009. Epub 2012 Aug 29.

PMID:
22939184
35.

Posttransplant recurrence of atypical hemolytic uremic syndrome.

Valoti E, Alberti M, Noris M.

J Nephrol. 2012 Nov-Dec;25(6):911-7. doi: 10.5301/jn.5000146. Review.

PMID:
22760880
36.

Predicting the physicochemical profile of diastereoisomeric histidine-containing dipeptides by property space analysis.

Vistoli G, Straniero V, Pedretti A, Fumagalli L, Bolchi C, Pallavicini M, Valoti E, Testa B.

Chirality. 2012 Jul;24(7):566-76. doi: 10.1002/chir.22056. Epub 2012 May 8.

PMID:
22566161
37.

Unichiral 2-(2'-pyrrolidinyl)-1,4-benzodioxanes: the 2R,2'S diastereomer of the N-methyl-7-hydroxy analogue is a potent α4β2- and α6β2-nicotinic acetylcholine receptor partial agonist.

Bolchi C, Gotti C, Binda M, Fumagalli L, Pucci L, Pistillo F, Vistoli G, Valoti E, Pallavicini M.

J Med Chem. 2011 Nov 10;54(21):7588-601. doi: 10.1021/jm200937t. Epub 2011 Oct 11.

PMID:
21942635
38.

Thiazole- and imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase.

Bolchi C, Pallavicini M, Bernini SK, Chiodini G, Corsini A, Ferri N, Fumagalli L, Straniero V, Valoti E.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5408-12. doi: 10.1016/j.bmcl.2011.07.003. Epub 2011 Jul 13.

PMID:
21802946
39.

New Ras CAAX mimetics: design, synthesis, antiproliferative activity, and RAS prenylation inhibition.

Bolchi C, Pallavicini M, Fumagalli L, Ferri N, Corsini A, Rusconi C, Valoti E.

Bioorg Med Chem Lett. 2009 Sep 15;19(18):5500-4. doi: 10.1016/j.bmcl.2009.07.065. Epub 2009 Jul 17.

PMID:
19666221
40.

An investigation into the influence of counterion on the RS-propranolol and S-propranolol skin permeability.

Cilurzo F, Minghetti P, Alberti E, Gennari CG, Pallavicini M, Valoti E, Montanari L.

J Pharm Sci. 2010 Mar;99(3):1217-24. doi: 10.1002/jps.21891.

PMID:
19653283
41.

5-(2-Pyrrolidinyl)oxazolidinones and 2-(2-pyrrolidinyl)benzodioxanes: synthesis of all the stereoisomers and alpha4beta2 nicotinic affinity.

Pallavicini M, Bolchi C, Binda M, Cilia A, Clementi F, Ferrara R, Fumagalli L, Gotti C, Moretti M, Pedretti A, Vistoli G, Valoti E.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):854-9. doi: 10.1016/j.bmcl.2008.12.002. Epub 2008 Dec 6.

PMID:
19097783
42.

[Reactive anxiety crisis: a unique case of work injury].

Taino G, Gazzoldi T, Marandola P, Valoti E, Fabris F, Imbriani M.

G Ital Med Lav Ergon. 2007 Jul-Sep;29(3 Suppl):630-1. Italian.

PMID:
18409875
43.

Modelling of full-length human alpha4beta2 nicotinic receptor by fragmental approach and analysis of its binding modes.

Pedretti A, Marconi C, Bolchi C, Fumagalli L, Ferrara R, Pallavicini M, Valoti E, Vistoli G.

Biochem Biophys Res Commun. 2008 May 2;369(2):648-53. doi: 10.1016/j.bbrc.2008.02.080. Epub 2008 Feb 25.

PMID:
18302933
44.

Peptidomimetic inhibitors of farnesyltransferase with high in vitro activity and significant cellular potency.

Bolchi C, Pallavicini M, Rusconi C, Diomede L, Ferri N, Corsini A, Fumagalli L, Pedretti A, Vistoli G, Valoti E.

Bioorg Med Chem Lett. 2007 Nov 15;17(22):6192-6. Epub 2007 Sep 8.

PMID:
17889533
45.

WB4101-related compounds: new, subtype-selective alpha1-adrenoreceptor antagonists (or inverse agonists?).

Pallavicini M, Budriesi R, Fumagalli L, Ioan P, Chiarini A, Bolchi C, Ugenti MP, Colleoni S, Gobbi M, Valoti E.

J Med Chem. 2006 Nov 30;49(24):7140-9.

PMID:
17125266
46.

Synthesis and alpha4beta2 nicotinic affinity of unichiral 5-(2-pyrrolidinyl)oxazolidinones and 2-(2-pyrrolidinyl)benzodioxanes.

Pallavicini M, Moroni B, Bolchi C, Cilia A, Clementi F, Fumagalli L, Gotti C, Meneghetti F, Riganti L, Vistoli G, Valoti E.

Bioorg Med Chem Lett. 2006 Nov 1;16(21):5610-5. Epub 2006 Aug 30. Erratum in: Bioorg Med Chem Lett. 2007 Dec 15;17(24):6914.

PMID:
16942873
47.

QSAR study for a novel series of ortho disubstituted phenoxy analogues of alpha1-adrenoceptor antagonist WB4101.

Pallavicini M, Fumagalli L, Gobbi M, Bolchi C, Colleoni S, Moroni B, Pedretti A, Rusconi C, Vistoli G, Valoti E.

Eur J Med Chem. 2006 Sep;41(9):1025-40. Epub 2006 Jun 5.

PMID:
16737760
48.

Construction of human ghrelin receptor (hGHS-R1a) model using a fragmental prediction approach and validation through docking analysis.

Pedretti A, Villa M, Pallavicini M, Valoti E, Vistoli G.

J Med Chem. 2006 Jun 1;49(11):3077-85.

PMID:
16722627
49.

QSAR study for a novel series of ortho monosubstituted phenoxy analogues of alpha1-adrenoceptor antagonist WB4101.

Fumagalli L, Bolchi C, Colleoni S, Gobbi M, Moroni B, Pallavicini M, Pedretti A, Villa L, Vistoli G, Valoti E.

Bioorg Med Chem. 2005 Apr 1;13(7):2547-59.

PMID:
15755656
50.

Synthesis and alpha4beta2 nicotinic affinity of 2-pyrrolidinylmethoxyimines and prolinal oxime ethers.

Pallavicini M, Moroni B, Bolchi C, Clementi F, Fumagalli L, Gotti C, Vailati S, Valoti E, Villa L.

Bioorg Med Chem Lett. 2004 Dec 6;14(23):5827-30.

PMID:
15501049

Supplemental Content

Loading ...
Support Center